Literature DB >> 13993152

Yellow fever vaccination in Malaya by subcutaneous injection and multiple puncture. Neutralizing antibody responses in persons with and without pre-existing antibody to related viruses.

C E SMITH, L H TURNER, P ARMITAGE.   

Abstract

Because of the risk of introduction of yellow fever to South-East Asia, comparative studies were made of yellow fever vaccination in Malayans who had a high prevalence of antibody to related viruses and in volunteers without related antibody. The proportions of positive neutralizing antibody responses to subcutaneous vaccination with 17D vaccine were not significantly different between volunteers with and without heterologous antibody but the degree of antibody response was greater in those without. The ID(50) of 17D in both groups was about 5 mouse intracerebral LD(50). Multiple puncture vaccination with 17D gave a much lower response rate than subcutaneous vaccination in volunteers with heterologous antibody. In both groups subcutaneous doses of about 50 mouse intracerebral LD(50) gave larger antibody responses than higher doses. The neutralizing indices and analysis of results were calculated by a method based on the survival time of the mice. This method, which has advantages over that of Reed & Muench, is fully described in an annex to this paper.

Entities:  

Keywords:  NEUTRALIZATION TESTS; VACCINATION; YELLOW FEVER; YELLOW FEVER VIRUS

Mesh:

Substances:

Year:  1962        PMID: 13993152      PMCID: PMC2555834     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  Yellow fever vaccination by scarification with 17D vaccine.

Authors:  H DE ROEVER-BONNET; J HOEKSTRA
Journal:  Trop Geogr Med       Date:  1958-09

2.  The use of survival time in the analysis of neutralization tests for serum antibody surveys.

Authors:  C E G SMITH; D R WESTGARTH
Journal:  J Hyg (Lond)       Date:  1957-06

3.  The distribution of antibodies to Japanese Encephalitis, dengue, and yellow fever viruses in five rural communities in Malaya.

Authors:  C E G SMITH
Journal:  Trans R Soc Trop Med Hyg       Date:  1958-05       Impact factor: 2.184

4.  A virus resembling Russian spring-summer encephalitis virus from an ixodid tick in Malaya.

Authors:  C E G SMITH
Journal:  Nature       Date:  1956-09-15       Impact factor: 49.962

5.  Isolation of three strains of type 1 dengue virus from a local outbreak of the disease in Malaya.

Authors:  C E G SMITH
Journal:  J Hyg (Lond)       Date:  1956-12

6.  Japanese encephalitis in Malaya. I. Isolation of virus and serologic evidence of human and equine infections.

Authors:  P Y PATERSON; H L LEY; C L WISSEMAN; W L POND; J E SMADEL; F H DIERCKS; H D G HETHERINGTON; P H A SNEATH; D H WITHERINGTON; W E LANCASTER
Journal:  Am J Hyg       Date:  1952-11

7.  Japanese type B encephalitis in Malaya.

Authors:  J H HALE; K A LIM; P H CHEE
Journal:  Ann Trop Med Parasitol       Date:  1952-11

8.  Vaccination by scarification with 17D yellow fever vaccine prepared at Yaba, Lagos, Nigeria.

Authors:  D A CANNON; F DEWHURST
Journal:  Ann Trop Med Parasitol       Date:  1953-12

9.  A preliminary evaluation of the immunizing power of chick-embryo 17 D yellow fever vaccine inoculated by scarification.

Authors:  G W A DICK
Journal:  Am J Hyg       Date:  1952-01

10.  A combined yellow fever-smallpox vaccine for cutaneous application.

Authors:  R G HAHN
Journal:  Am J Hyg       Date:  1951-07
  10 in total
  8 in total

1.  Evaluation of survival in challenge experiments.

Authors:  F D Liddell
Journal:  Microbiol Rev       Date:  1978-03

Review 2.  The global distribution of yellow fever and dengue.

Authors:  D J Rogers; A J Wilson; S I Hay; A J Graham
Journal:  Adv Parasitol       Date:  2006       Impact factor: 3.870

3.  A yellow fever vaccine free from avian leucosis viruses.

Authors:  C C Draper
Journal:  J Hyg (Lond)       Date:  1967-12

4.  Leukaemia and neoplastic processes treated with Langat and Kyasanur Forest disease viruses: a clinical and laboratory study of 28 patients.

Authors:  H E Webb; G Wetherley-Mein; C E Smith; D McMahon
Journal:  Br Med J       Date:  1966-01-29

5.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

6.  YELLOW FEVER VACCINATION IN MALAYA BY SUBCUTANEOUS INJECTION AND MULTIPLE PUNCTURE. HAEMAGGLUTININ-INHIBITING ANTIBODY RESPONSES IN PERSONS WITH AND WITHOUT PRE-EXISTING ANTIBODY.

Authors:  C E SMITH; D A MCMAHON; L H TURNER
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

7.  17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.

Authors:  Reinaldo M Martins; Maria de Lourdes S Maia; Roberto Henrique G Farias; Luiz Antonio B Camacho; Marcos S Freire; Ricardo Galler; Anna Maya Yoshida Yamamura; Luiz Fernando C Almeida; Sheila Maria B Lima; Rita Maria R Nogueira; Gloria Regina S Sá; Darcy A Hokama; Ricardo de Carvalho; Ricardo Aguiar V Freire; Edson Pereira Filho; Maria da Luz Fernandes Leal; Akira Homma
Journal:  Hum Vaccin Immunother       Date:  2013-01-30       Impact factor: 3.452

Review 8.  Is there a risk of yellow fever virus transmission in South Asian countries with hyperendemic dengue?

Authors:  Suneth B Agampodi; Kolitha Wickramage
Journal:  Biomed Res Int       Date:  2013-12-03       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.